This company has shut down. Aerami Therapeutics is no longer operating — its last tracked round was a Series B in 2022.
Explore the Startup GraveyardAerami Therapeutics focuses on developing novel inhaled therapies for the treatment of chronic diseases.
Aerami Therapeutics has raised $5.4M in total funding. The most recent round was Series B. The last funding was announced in September 2022.
Aerami Therapeutics's investors include SternAegis, Molex Ventures, John Patton.
Aerami Therapeutics is headquartered in Durham, United States.
Aerami Therapeutics focuses on developing novel inhaled therapies for the treatment of chronic diseases.
Aerami Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aerami Therapeutics — Funding & Investors." VCBacked, September 20, 2022, https://www.vcbacked.co/company/aerami-therapeutics. Accessed August 16, 2026.
VCBacked. (2022). Aerami Therapeutics — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/aerami-therapeutics
{{cite web |title=Aerami Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aerami-therapeutics |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated